Arkolith/Insider Trading/BBIO/Form 4

Kumar Neil

Chief Executive Officer, DirectorBridgeBio Pharma, Inc. (BBIO) · full profile →Form 4 · filed Apr 13, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$6.0M
Net Open-Market Flow
-$6.0M
Transactions
8
8 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 10, 2026Sell(S)20K$74.60$1.5M596K
Apr 10, 2026Sell(S)20K$74.60$1.5M4.4M
Apr 9, 2026Sell(S)8K$75.55$567K616K
Apr 9, 2026Sell(S)7K$73.64$521K4.4M
Apr 9, 2026Sell(S)7K$73.64$530K628K
Apr 9, 2026Sell(S)8K$75.53$589K4.4M
Apr 9, 2026Sell(S)5K$74.57$382K4.4M
Apr 9, 2026Sell(S)5K$74.60$395K623K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000361) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML